Implementation of phase 0 trials

被引：0
|
作者：
Schellens, J. H. M. [1 ]
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)71954-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [41] Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials
    Vinson, J.
    Mathew, P.
    Beer, T. M.
    Carducci, M. A.
    Oh, W.
    Small, E.
    Wilding, G.
    Higano, C.
    Hussain, M.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Communication in the context of phase I clinical trials in oncology: Implementation and evaluation of training programs
    Rouby, Pascal
    Hollebecque, Antoine
    Bahleda, Ratislav
    Deutsch, Eric
    Gomez-Rocca, Carlos
    Angevin, Eric
    Rouge, Thibault de la Motte
    Soria, Jean-Charles
    Dauchy, Sarah
    BULLETIN DU CANCER, 2015, 102 (02) : 174 - 181
  • [43] A Guide to Implementation Science for Phase 3 Clinical Trialists Designing Trials for Evidence Uptake
    Van Spall, Harriette G. C.
    Desveaux, Laura
    Finch, Tracy
    Lewis, Cara C.
    Mensah, George A.
    Rosenberg, Yves
    Singh, Kavita
    Venter, Francois
    Weiner, Bryan J.
    Zannad, Faiez
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (20) : 2063 - 2072
  • [44] The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries
    Kapiriri, Lydia
    Lavery, James V.
    Singer, Peter A.
    Mshinda, Hassan
    Babiuk, Lorne
    Daar, Abdallah S.
    BMC PUBLIC HEALTH, 2011, 11
  • [45] The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries
    Lydia Kapiriri
    James V Lavery
    Peter A Singer
    Hassan Mshinda
    Lorne Babiuk
    Abdallah S Daar
    BMC Public Health, 11
  • [46] The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I–III Studies
    Nicholas S. Cho
    Weng Kee Wong
    Phioanh L. Nghiemphu
    Timothy F. Cloughesy
    Benjamin M. Ellingson
    Current Oncology Reports, 2023, 25 : 1047 - 1055
  • [47] Phase 0 clinical trials in cancer drug development: From FDA guidance to clinical practice
    Kinders, Robert
    Parchment, Ralph E.
    Ji, Jay
    Kummar, Shivaani
    Murgo, Anthony J.
    Gutierrez, Martin
    Collins, Jerry
    Rubinstein, Larry
    Pickeral, Oxana
    Steinberg, Seth M.
    Yang, Sherry
    Hollingshead, Melinda
    Chen, Alice
    Helman, Lee
    Wiltrout, Robert
    Simpson, Mel
    Tomaszewski, Joseph E.
    Doroshow, James H.
    MOLECULAR INTERVENTIONS, 2007, 7 (06) : 325 - 334
  • [48] A naive pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens
    van der Heijden, Lisa
    van Nuland, Merel
    Beijnen, Jos
    Huitema, Alwin
    Dorlo, Thomas
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (02): : 258 - 268
  • [49] Introducing a 'Phase 0' in Clinical Trials with Precise Organoid-based Disease Models.
    Tindle, Courtney
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2022, 58 (SUPPL 1) : S5 - S5
  • [50] Cell cycle biomarker discovery for phase 0 clinical trials in type II endometrial cancer
    Stone, R. L.
    Beavis, A. L.
    Baras, A.
    Wang, T. L.
    Yen, T. T.
    Chui, M. H.
    Lin, S. F.
    Bahadirli-Talbott, A.
    Temkin, S. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 118 - 118
12345